GLP-1 Medications Increase Testosterone Levels in Men With Obesity
New research shows semaglutide, dulaglutide, and tirzepatide can increase testosterone levels in men with obesity, adding another ancillary benefit to the GLP-1 portfolio.
#semaglutide
46 stories
India Semaglutide Trademark Disputes: Dr. Reddy's Renames Drug After Court Concerns
Dr. Reddy's will rename its semaglutide drug from 'Olymviq' to 'Olymra' after Delhi High Court flagged similarity to Novo Nordisk's 'Ozempic'. Fierce competition in India's generic market.
Washington Post: Comprehensive Guide to GLP-1 Drug Effects on the Body
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
Biocon Skips India's Crowded Generic Semaglutide Market, Eyes Global Expansion
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.
Eli Lilly and Novo Nordisk Strike MFN Deals to Lower GLP-1 Prices
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
Orforglipron Outperforms Oral Semaglutide in Phase 3 ACHIEVE-3 Trial
Eli Lilly's oral orforglipron demonstrated superior HbA1c reduction and weight loss vs oral semaglutide in Phase 3, strengthening the case ahead of an April FDA decision.
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular and Stroke Benefits
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.
Experts Propose 10-Year Trial to Test GLP-1 Drugs for Cancer Prevention
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
FDA Approves Higher 2 mg Dose of Ozempic for Type 2 Diabetes
The FDA approved a new 2 mg dose of Ozempic (semaglutide) injection, providing an additional option for patients needing more intensive glycemic management.
Semaglutide Linked to 42% Drop in Psychiatric Hospital Visits
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.